Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2

Status

Completed 25Terminated 13Unknown 8Active not recruiting 6Withdrawn 4Not yet recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Small Cell Lung Carcinoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lung Neoplasms 10Burkitt Lymphoma 9Leukemia, Myeloid, Acute 8Lymphoma 7Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Sarcoma, Ewing 3Sarcoma 3Rhabdomyosarcoma 3Rhabdoid Tumor 3Retinoblastoma 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroblastoma 3Neoplasms, Germ Cell and Embryonal 3Myelodysplastic Syndromes 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Immunoblastic Lymphadenopathy 3Seminoma 2

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × Etoposide × Clear all
NCT04092283 2026-05-29

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
660 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06564844 2026-05-22

TROPION-Lung12

AstraZeneca

Phase 3 Active not recruiting
25 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04380636 2026-05-15

MK-7339-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
870 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03141359 2026-02-05

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Wake Forest University Health Sciences

Phase 2 Active not recruiting
61 enrolled 25 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
611 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

AstraZeneca

Phase 2 Active not recruiting
247 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡